ACP
BIB icon

Aviance Capital Partners’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Aviance Capital Partners’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,870
Closed -$682K – 221
2014
Q4 		$682K Buy
+10,870
New +$638K 0.25% 122

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return

Aviance Capital Partners's BIB Position: Q1 2015 in Review

Aviance Capital Partners sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2015, closing a stake of 10,870 shares — an estimated $682K sold.

Aviance Capital Partners first reported a position in BIB in Q4 2014 and held it in 1 quarter. The position peaked at $682K in Q4 2014. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2015.

  • Aviance Capital Partners reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2015 after selling out during the quarter.
  • Aviance Capital Partners sold 10,870 ProShares Ultra NASDAQ Biotechnology shares in Q1 2015, an estimated $682K.
  • Aviance Capital Partners first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 1 quarter.
  • Aviance Capital Partners's ProShares Ultra NASDAQ Biotechnology position peaked at $682K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2015.

Based on Aviance Capital Partners's 13F filing for Q1 2015, filed 5 May 2015.